Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2Cl.Pt.2H3N |
Molecular Weight | 300.051 |
Optical Activity | NONE |
Additional Stereochemistry | Yes |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
Stereo Comments | SP-4-2 |
SHOW SMILES / InChI
SMILES
N.N.[Cl-].[Cl-].[Pt++]
InChI
InChIKey=LXZZYRPGZAFOLE-UHFFFAOYSA-L
InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
Molecular Formula | H3N |
Molecular Weight | 17.0305 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Pt |
Molecular Weight | 195.084 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24435208https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdfftp://ftp.nrg.eu/pub/www/nrg/nrglib/2004/immobilisation_of_iodine.pdfCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00515 | https://www.ncbi.nlm.nih.gov/pubmed/27736024 | https://www.ncbi.nlm.nih.gov/pubmed/25159039
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24435208https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018057s083lbl.pdfftp://ftp.nrg.eu/pub/www/nrg/nrglib/2004/immobilisation_of_iodine.pdf
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00515 | https://www.ncbi.nlm.nih.gov/pubmed/27736024 | https://www.ncbi.nlm.nih.gov/pubmed/25159039
There is no available sources on the medical use of platinum iodide. The salt is insoluble.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9865478
Curator's Comment: With the injection of cisplatin into mice 3 h after the LPS treatment, platinum was detected in the CCR during the 7 days after the injection, while platinum was not detected in the CCR of cisplatin-injected mice without LPS pretreatment and of mice simultaneous treated with cisplatin and LPS.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27736024 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CISPLATIN Approved UseCisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date1978 |
|||
Primary | CISPLATIN Approved UseCisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date1978 |
|||
Primary | CISPLATIN Approved UseCisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date1978 |
|||
Primary | CISPLATIN Approved UseCisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. Launch Date1978 |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis of tetracyclic chromenones via platinum(II) chloride catalysed cascade cyclization of enediyne-enones. | 2014 Feb 28 |
|
Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen. | 2017 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:18:53 GMT 2023
by
admin
on
Fri Dec 15 15:18:53 GMT 2023
|
Record UNII |
Q20Q21Q62J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C798
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
WHO-ATC |
L01XA01
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
238607
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
221906
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
WHO-VATC |
QL01XA01
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
NDF-RT |
N0000175413
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
134800
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
536616
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
447514
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
NDF-RT |
N0000175073
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/13/1169
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
867921
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
LIVERTOX |
NBK548160
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
557716
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
NCI_THESAURUS |
C1450
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
783620
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
133200
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D002945
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
DTXSID4024983
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
15663-27-1
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
100000088223
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL11359
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
4392
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
119875
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
C376
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
Q20Q21Q62J
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
84691
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
Cisplatin
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
3939
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
239-733-8
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
5343
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
4426
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
27899
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
CISPLATIN
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | Description: White to yellowish crystals or a yellow powder.Solubility: Slightly soluble in water; sparingly soluble in dimethylformamide R; practically insoluble in methanol R.Category: Cytotoxic drug.Storage: Cisplatin should be kept in a tightly closed container, protected from light, and stored at a temperature between 2 and 8?C.Additional information: CAUTION: Cisplatin must be handled with care, avoiding contact with the skin and inhalation of airborneparticles.When heated, it blackens at about 270 ?C with decomposition. | ||
|
CISPLATIN
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
1134357
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
DB00515
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
m3586
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
Q20Q21Q62J
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | |||
|
2555
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB07483MIG
Created by
admin on Fri Dec 15 15:18:53 GMT 2023 , Edited by admin on Fri Dec 15 15:18:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
OCCURS INTRACELLULARLY
|
||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE ACTIVE -> PRODRUG |
OCCURS INTRACELLULARLY
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
ASSAY (HPLC)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||